Marksans Pharma’s shares tumbled 13% in today’s trade after the company posted a disappointing set of numbers for the first quarter of FY26. The stock, which opened at ₹211.15 against the previous close of ₹210.08, slipped to an intraday low of ₹181.45.
For Q1FY26, the pharmaceutical major reported a sharp 34.3% year-on-year decline in consolidated net profit, which fell to ₹58.3 crore from ₹88.7 crore in the same quarter last year. Revenue, however, rose 5% to ₹620 crore compared to ₹590.6 crore a year ago, indicating that higher sales were not enough to offset the squeeze on margins. Operational performance also came under pressure, with EBITDA slipping 22% to ₹100 crore from ₹128 crore last year, while margins contracted to 16.1% from 21.7% in the year-ago period.
The stock remained volatile throughout the session, touching a high of ₹214.47 before the sharp fall. It now trades not far from its 52-week low of ₹171, and well below its 52-week high of ₹358.70.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
